Clinical trials: Stage III
Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy
Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy
Study to evaluate the Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy
- Trial name
- CIDP (NCT02638207)
- Testing
- NewGam
- Where
- 26 sites in Bulgaria, Canada and 7 more
- Volunteers
- 142 people
- Sponsor
- Octapharma
Small-Cell Lung Cancer
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage…
- Trial name
- IMforte (NCT05091567)
- Testing
- Atezolizumab, Lurbinectedin, Carboplatin
- Where
- 93 sites in United States, Belgium and 11 more
- Volunteers
- 660 people
- Sponsor
- Hoffmann-La Roche
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens plus radiation therapy in treating patients who have stage III or stage IV endometrial cancer.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
- Trial name
- NCT00006011
- Testing
- Doxorubicin Hydrochloride, Cisplatin, Filgrastim
- Where
- United States
- Volunteers
- 659 people
- Sponsor
- Gynecologic Oncology Group
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00089011
- Testing
- fludarabine phosphate, total-body irradiation, mycophenolate mofetil
- Where
- 5 sites in United States, Italy
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsing-remitting Multiple Sclerosis
Study of Evobrutinib in Participants With RMS
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with Relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT04032171
- Testing
- Evobrutinib, Avonex®
- Where
- 2 sites in United States, Germany
- Volunteers
- 1 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This phase II trial is studying the how well saracatinib works in treating patients with metastatic or recurrent head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00513435
- Testing
- saracatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Two independent study parts (i.e. Part A and Part B) are included in this trial. Part A will evaluate empagliflozin 10 mg + linagliptin and Part B will evaluate empagliflozin 25 mg + linagliptin.
- Trial name
- NCT02489968
- Testing
- empagliflozin 10 mg + linagliptin 5 mg, empagliflozin 10 mg, empagliflozin 25 mg + linagliptin 5 mg
- Where
- 83 sites in Japan
- Volunteers
- 880 people
- Sponsor
- Boehringer Ingelheim
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
This phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma.
- Conditions
- Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Trial name
- NCT01026220
- Testing
- bleomycin sulfate, doxorubicin hydrochloride, liposomal vincristine sulfate
- Where
- 177 sites in United States, Australia and 3 more
- Volunteers
- 166 people
- Sponsor
- Children's Oncology Group
Head and Neck Cancer, Carcinoma, Squamous Cell
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
We propose to combine lapatinib with RT alone in patients with locally advanced head and neck cancer who cannot tolerate chemotherapy.
- Conditions
- Head and Neck Cancer, Carcinoma, Squamous Cell, Head and Neck Cancers
- Trial name
- NCT00490061
- Testing
- Lapatinib, Radiotherapy (radiation), G.E. Healthcare 1.5T MR, systems revision 12.0 M5
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Quynh-Thu Le
Myelogenous Leukemia
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
In this study, the efficacy and safety of nilotinib 400 mg twice daily, will be compared with imatinib 400 mg twice daily in patients with a suboptimal response to imatinib for their Philadelphia chromosome-positive (Ph+) Chronic…
- Trial name
- ENEST (NCT00519090)
- Testing
- Imatinib, Nilotinib (AMN107)
- Where
- 80 sites in United States, Australia and 8 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Sarcoma
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00217620
- Testing
- sorafenib
- Where
- 184 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
RATIONALE: Melphalan, a chemotherapeutic agent, has been found to be an effective treatment choice for destroying myeloma cells, especially when given at high (bone marrow ablative) doses.
- Conditions
- Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma
- Trial name
- NCT00112827
- Testing
- total marrow irradiation, melphalan, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Hemophilia B
A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
This study will examine the safety, pharmacokinetics and efficacy of rIX-FP for the control and prevention of bleeding episodes in subjects who have previously received factor replacement therapy for hemophilia B.
- Trial name
- NCT01496274
- Testing
- rIX-FP
- Where
- 30 sites in United States, Austria and 8 more
- Volunteers
- 63 people
- Sponsor
- CSL Behring
Malignant Pleural Effusion
Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT01661790
- Testing
- Bevacizumab, Cisplatin
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Chinese PLA General Hospital
Central Nervous System Diseases
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients
The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of brain or spine diseases in patients of Chinese origin.
- Trial name
- NCT00395460
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875), Magnevist
- Where
- 4 sites in China
- Volunteers
- 147 people
- Sponsor
- Bayer
Hepatitis C, Chronic
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
The aim of the study is to confirm efficacy and safety of treatment with 600 mg of BID BI 207127 in combination with 120 mg QD FDV and RBV for 16 or 24 weeks in target chronically infected HCV GT1b treatment naïve patients…
- Trial name
- NCT01728324
- Testing
- Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment
- Where
- 109 sites in United States, Australia and 10 more
- Volunteers
- 496 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Carcinoma
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with…
- Trial name
- IMpower133 (NCT02763579)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Etoposide
- Where
- 114 sites in United States, Australia and 19 more
- Volunteers
- 503 people
- Sponsor
- Hoffmann-La Roche
Metastatic Melanoma
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both ipilimumab and GM-CSF are intended to work with the body's own immune system to attack melanoma cells in the body.
- Trial name
- NCT02009397
- Testing
- Ipilimumab, GM-CSF
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Louisville
Stage IIIA Non-Small Cell Lung Cancer
Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC
The purpose of this research study is to determine whether giving cisplatin and nab-paclitaxel before surgery will reduce the presence of disease in certain areas of the lung at the time of surgery.
- Trial name
- LCCC1407 (NCT02276560)
- Testing
- Neoadjuvant Cisplatin, nab-paclitaxel, Adjuvant Cisplatin,nab-paclitaxel, Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line metastatic settings, led to a raise of patients presenting with metastatic breast cancer after treatment with these agents.
- Trial name
- NCT01095003
- Testing
- Vinflunine plus Capecitabine, Capecitabine
- Where
- 110 sites in Argentina, Belarus and 19 more
- Volunteers
- 770 people
- Sponsor
- Pierre Fabre Medicament
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.